Prof Fran Balkwill Barts Cancer InstituteWhen it comes to cancer immunotherapy drug development, one of the challenges is that we can’t accurately predict from preclinical mouse models what will happen in people. The result is a rush into the clinic to test in human subjects.

We do need better preclinical models, which is why it was interesting to hear recently on an episode of Health Check (BBC World Service) about a 3D tumour model that is being developed at Barts Cancer Institute.

Professor Fran Balkwill (pictured), who leads the Centre for Cancer and Inflammation, kindly spoke to BSB about the work she and colleagues are doing to model the tumour microenvironment (TME) in high-grade serous ovarian cancer.

Subscribers can login to read more or you can purchase access below:

Posted by 

Purchase Access to Premium Content

PLEASE READ BEFORE YOU BUY. Click on blue icon to purchase a PERSONAL, INDIVIDUAL license to premium content. Please READ our TERMS OF USE before purchasing (link at bottom of page): You are NOT PERMITTED to share access or copies of posts. If you work for a CONSULTING FIRM, AGENCY, or are in PR, COMMUNICATIONS OR MEDIA (that includes JOURNALISTS & WRITERS), you cannot purchase an INDIVIDUAL license through this site without prior approval (even if your use is personal) and typically a CORPORATE license will be required. Please CONTACT US to discuss how you might use our content & obtain a quote for the appropriate license. Rates may change without notice and are non-refundable. If you are in any doubt about whether you can buy through the blue icon, PLEASE CONTACT US first. Please note that we do not collect or remit any sales taxes. The purchaser is solely responsible for ensuring compliance with tax laws where they reside or use our content and for the reporting and payment, at their expense, of any use tax or other taxes that may be due as a result of this purchase. An accountant, tax advisor or lawyer should be consulted for advice on any obligation.